SYNE1 and neoplasm: We also compared immune cell infiltration between those with SYNE1 mutation type (mt) and those with wild type (wt), and evaluated the utility of SYNE1 mutation as a ICB biomarker using the tumor immune dysfunction and exclusion (TIDE) algorithm [21].